Project Grant R03CA304032
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$158K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This Project Grant award of $160,330, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program, supports research to investigate the biochemical determinants of genome instability induced by eukaryotic topoisomerase II. The research aims to understand how the biochemical properties of topoisomerases, along with other factors like chromatin structure and DNA repair pathways, contribute to genome instability. Key project...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University will provide $713,601 in funding over a 5-year period from August 1, 2025 to July 31, 2030. The project aims to characterize the mechanisms by which defects in the homologous recombination (HR) DNA repair pathway influence the efficacy of immune checkpoint blockade (ICB) therapies in cancer treatment....
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
This Project Grant award of $315,143.00 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports clinical trial research in the oncology landscape. The award, which has an ultimate completion date of August 31, 2029, is being provided to The Ohio State University, a leading public research university. Through this funding, The Ohio State University will conduct innovative cancer research focused on understanding cancer mechanisms, developing new diagnostic and...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $541,682 to The Trustees of Columbia University in the City of New York for a 5-year period from July 3, 2024 to June 30, 2029. The project aims to better understand the mechanisms responsible for the assembly of DNA repair domains in cancer cells and evaluate the consequences of these domains following treatment with chemotherapeutic drugs....
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research Program (CFDA 93.396), provides USD 153,000 to the University of Toledo to optimize the "knocksideways" technique to analyze the interactions between the MAD1:MAD2 protein subcomplex and other subcomplexes that contribute to the spindle assembly checkpoint and chromosomal stability. The goal is to gain a better understanding of the fundamental biological mechanisms underlying cancer...
The National Institute of General Medical Sciences (NIGMS) awarded a $445,000 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, Massachusetts. The grant, which runs from January 22, 2025 to December 31, 2029, supports research to elucidate the molecular mechanisms of DNA double-strand break repair by homologous recombination. The goal of this project is to define the processes that allow cells to...
The National Cancer Institute (NCI) awarded a $487,393 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY, effective December 1, 2024 through November 30, 2029. The grant supports research to determine the role of RAD52, HELQ, and POLQ proteins in backup DNA double-strand break repair pathways, which are critical for the survival of homologous recombination deficient (HRD) cancer cells. The research aims to...
This federal Project Grant award of $597,573 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports structural and dynamic studies of large protein and protein-nucleic acid complexes and assemblies that play key roles in human health and disease. The primary objectives are to: (1) provide atomic-resolution insights into the structure, dynamics, interactions, and function of nucleosomes and large nucleosome arrays...
This $2,556,071 Project Grant award was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to The University of Texas Health Science Center at San Antonio. The award supports a collaborative research program focused on elucidating the mechanisms by which the BRCA1-BARD1 and BRCA2 tumor suppressors promote homologous recombination (HR) DNA repair, and how this is negatively regulated by the 53BP1 axis to favor the use of...